Arzneimittel und Biotechnologie

Cleary Gottlieb vertritt viele der weltweit größten Biotechnologie- und Pharmaunternehmen bei gesellschaftsrechtlichen Transaktionen, in kartell- und aufsichtsrechtlichen Angelegenheiten sowie in Prozessen und Schiedsverfahren, die für die Branche grundlegende Bedeutung haben. Darüber hinaus beraten wir Finanzinstitute, die diese Unternehmen bei ihren Finanzierungsaktivitäten am Kapitalmarkt unterstützen. Durch unser weltweites Netzwerk von sechzehn Büros können unsere Anwältinnen und Anwälte Mandanten über geografische und rechtliche Grenzen hinweg umfassend beraten. Dabei helfen sie unseren Mandanten insbesondere, die aufsichtsrechtlichen Anforderungen verschiedener Rechtsordnungen zu erfüllen, um so den Weg für angestrebte Zusammenschlüsse, Übernahmen, Joint Ventures und andere Transaktionen freizumachen.

Nachfolgend sind wichtige Beispiele unserer Beratungstätigkeit aufgeführt:

    • Counsel to Crucell on U.S. securities, M&A and tax matters in its $2.4 billion acquisition by Johnson & Johnson, involving a U.S./Dutch tender offer for the 82% of Crucell that Johnson & Johnson does not already own.

    • Counsel to TPG on intra-consortium and LP co-investment aspects of its $5.9 billion leveraged acquisition, together with CPP Investment Board Private Holdings and Leonard Green & Partners, L.P., of IMS Health, one of the largest leveraged buyouts completed during the financial crisis.

    • Counsel to Merck & Co. on the antitrust aspects in all non-U.S. jurisdictions of its $41 billion merger with Schering-Plough.

    • Regular EC law counsel to Merck & Co. on a cutting-edge issues, including a precedent-setting European Court of Justice win regarding the interpretation of the World Trade Organization’s Agreement on Trade Related Aspects of Intellectual Property Rights and in antitrust challenges by generic companies.

    • Counsel to Kindred Healthcare in its takeover of RehabCare and in the simultaneous spin-off and merger of the pharmacy businesses of Kindred and Amerisource Bergen to form a new public company, PharMerica.

    • Corporate and antitrust counsel to GlaxoSmithKline in its $2.9 billion acquisition of Stiefel Laboratories, as well as its acquisitions of Reliant Pharmaceuticals, Sirtris Pharmaceuticals, Praecis Pharmaceuticals, CNS, ID Biomedical and Corixa.

    • Counsel to GlaxoSmithKline in a number of litigations including a U.S. class action alleging that import restrictions imposed by pharmaceutical companies to prevent illegal diversion of Canadian products to U.S. markets violate federal antitrust laws, and U.S. class actions relating to allegations of patent misuse and the enforcement of patents for Augmentin and HIV treatments.

    • Counsel to Goldman Sachs as financial advisor to Immucor, Inc. in the $1.97 billion acquisition of Immucor by an affiliate of TPG Capital. Also counsel to Goldman Sachs as financial advisor to Valeant Pharmaceuticals in its $5.7 billion unsolicited proposal to acquire Cephalon and a related consent solicitation to replace the directors of Cephalon.

    • Counsel to the underwriters, led by BNP Paribas, BofA Merrill Lynch, JP Morgan and Societe General, in a $7 billion SEC-registered bond offering by sanofi-aventis, the company’s first registered debt offering.

    • Counsel to Warburg Pincus in its $4.5 billion cash acquisition of Bausch & Lomb.

    • Counsel to TPG, The Blackstone Group, Goldman Sachs Capital Partners and KKR in their $11.4 billion acquisition of Biomet—one of the largest LBOs in the healthcare industry.

    • Counsel to TPG in its proposed $800 million acquisition of 50% of SIA International, Russia’s largest pharmaceutical distributor, the largest private equity investment in Russia at the time of announcement.

    • Counsel to Medtronic in connection with its acquisitions of Invatec and two related companies, Fogazzi and KRAUTH Cardio-Vascular.

    • Counsel to two dozen investment banks, including Citigroup Global Markets, in class actions brought by holders of debt and equity securities issued by HealthSouth Corporation. We succeeded in obtaining the dismissal of all of our clients from these cases.


Highlights unserer Praxis

Medtronic in $42.9 Billion Acquisition of Covidien

Biomet in $13.35 Billion Merger with Zimmer

Sterigenics in $805 Million Acquisition of Nordion

GlaxoSmithKline in Major Transaction with Novartis

Summary Judgment in Antitrust Litigation Brought Against Sanofi U.S.

Warburg Pincus and Bausch + Lomb in $8.7 Billion Acquisition of Bausch + Lomb by Valeant

Sanofi Wins Appeal and Defeats Rhodia’s €1.6 Billion Claim

Forest Laboratories in $1.8 Billion Notes Offering

Warner Chilcott in Acquisition by Actavis

Envision Pharmaceutical Holdings in Its Acquisition of Laker Software

Simcere Pharmaceutical Group in Going-Private Transaction

TPG in Acquisition of Envision Pharmaceutical Holdings

Agilent Technologies in $2.2 Billion Acquisition of Dako

GlaxoSmithKline in $3 Billion Notes Offering

Sanofi in $1.5 Billion SEC-Registered Bond Offering

Elan Corporation in $850 Million Notes Offering

CFR Pharmaceuticals in Transactions to Fund Major Acquisition